
Switzerland paves the way for genome editing
Following in the footsteps of the UK, Switzerland wants to exempt genome editing and targeted mutagenesis in plant breeding from the Swiss Genetic...

Enzymaster raises $45m in Series C round
The Series C financing round was led by Yuanbio Venture Capital with While Bayland Capital, Puhua Capital, C&D Emerging Capital, Hansoh...

Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

Unilever launches $120m venture with Genomatica
US biotechnology company Genomatica is a producer of sustainable materials derived from plant- or waste-based feedstocks instead of fossil fuels....

Switzerland shows sustained growth of biotech sector
Capital investments in Swiss biotech companies reached the second-best amount ever with CHF3.33bn in the second year of the pandemic, according to...

AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...